1. Home
  2. HKPD vs MBIO Comparison

HKPD vs MBIO Comparison

Compare HKPD & MBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

HKPD

Hong Kong Pharma Digital Technology Holdings Limited Ordinary shares

HOLD

Current Price

$0.42

Market Cap

6.9M

Sector

Health Care

ML Signal

HOLD

MBIO

Mustang Bio Inc.

HOLD

Current Price

$0.73

Market Cap

5.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HKPD
MBIO
Founded
2016
2015
Country
Hong Kong
United States
Employees
27
N/A
Industry
Other Pharmaceuticals
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.9M
5.6M
IPO Year
N/A
2023

Fundamental Metrics

Financial Performance
Metric
HKPD
MBIO
Price
$0.42
$0.73
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
397.2K
63.5K
Earning Date
08-14-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
98.99
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.32
$0.53
52 Week High
$2.58
$7.00

Technical Indicators

Market Signals
Indicator
HKPD
MBIO
Relative Strength Index (RSI) 37.85 48.92
Support Level $0.34 $0.69
Resistance Level $0.71 $0.82
Average True Range (ATR) 0.06 0.09
MACD -0.00 0.00
Stochastic Oscillator 35.46 33.38

Price Performance

Historical Comparison
HKPD
MBIO

About HKPD Hong Kong Pharma Digital Technology Holdings Limited Ordinary shares

Cellyan Biotechnology Co Ltd formerly, Hong Kong Pharma Digital Technology Holdings Ltd operates in two main categories: OTC pharmaceutical cross-border e-commerce supply chain services, conducted through its Hong Kong subsidiary, Joint Cross Border, which it refers to as the Supply Chain Services division, and OTC pharmaceutical cross-border procurement and distribution, conducted through its Hong Kong subsidiary, V-Alliance, which it referred to as the Procurement and Distribution division. Based in Hong Kong, Joint Cross Border has established itself as a provider of third-party supply chain services in Mainland China's OTC pharmaceutical cross-border e-commerce market.

About MBIO Mustang Bio Inc.

Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs into potential cures for difficult-to-treat cancers. It acquires rights to these technologies by licensing or otherwise acquiring an ownership interest in the technologies, funding their research and development, and eventually either out-licensing or bringing the technologies to market. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.

Share on Social Networks: